Tag: Igf 1r inhibitor

According to clinical trial data, diarrhea is a recognized side effect of Tepezza, affecting between 12% and 27.4% of patients [1.2.1, 1.6.8]. So, can Tepezza cause diarrhea, and what should patients understand about this common gastrointestinal issue?

Tepezza contains the active ingredient teprotumumab-trbw, which is a biologic drug produced from living cells, not a traditional chemically synthesized medication. This medication represents a specialized, targeted approach to therapy, marking a significant departure from older treatments for Thyroid Eye Disease (TED), the condition it is approved to treat. So, what is Tepezza made of and how does its unique composition work?

According to the American Thyroid Association, Tepezza (teprotumumab) is not a chemotherapy drug but a targeted biologic therapy for an autoimmune condition known as Thyroid Eye Disease (TED). The misconception about whether is tepezza a form of chemotherapy? often arises due to its intravenous administration and potential side effects, but its mechanism of action is entirely distinct from the non-specific, cytotoxic effects of cancer-fighting agents.

In 2020, Tepezza (teprotumumab-trbw) made history as the first medication specifically approved by the FDA for the treatment of Thyroid Eye Disease (TED). This groundbreaking medication is not a small-molecule drug like many traditional treatments but is, in fact, a fully human monoclonal antibody. It works by targeting the underlying cause of the disease rather than just managing the symptoms.

In 2020, the FDA approved Tepezza as the first and only medication to address the underlying cause of Thyroid Eye Disease (TED), rather than just managing symptoms. But **what type of medication is Tepezza**? It is a targeted biologic known as a monoclonal antibody that has revolutionized the treatment landscape for this autoimmune condition.

In 2020, the U.S. Food and Drug Administration (FDA) approved teprotumumab (brand name Tepezza) as the first and only medication specifically for treating Thyroid Eye Disease (TED). This was a major breakthrough for a condition that had previously lacked targeted, non-surgical drug options. For patients wondering what is the new drug for TED, Tepezza represents a targeted, non-surgical advancement in treatment.